Cabaletta Bio’s (CABA) treatment of myasthenia gravis, resecabtagene autoleucel, was granted FDA orphan designation, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating
- Cabaletta Bio Advances in Autoimmune Therapy Development
- Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating
- Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
- Cabaletta Bio reports Q3 EPS (44c), consensus (46c)